Doris Riether

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi Selective cannabinoid receptor 2 modulators: a patent review 2009 - present
    Doris Riether
    Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 65, D 88397 Biberach an der Riß, Germany
    Expert Opin Ther Pat 22:495-510. 2012
  2. ncbi Nonsteroidal dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics
    Doris Riether
    Department of Medicinal Chemistry, Department of Immunology and Inflammation, and Drug Discovery Support, Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, Connecticut 06877, USA
    J Med Chem 53:6681-98. 2010
  3. ncbi 1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability
    Doris Riether
    Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 21:2011-6. 2011
  4. ncbi 5-Aminomethylbenzimidazoles as potent ITK antagonists
    Doris Riether
    Medicinal Chemistry Department, Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Rd PO Box 368, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 19:1588-91. 2009
  5. ncbi Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters
    Renee Zindell
    Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877 0368, USA
    Bioorg Med Chem Lett 21:4276-80. 2011
  6. ncbi Morpholine containing CB2 selective agonists
    Renee Zindell
    Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877 0368, USA
    Bioorg Med Chem Lett 19:1604-9. 2009

Detail Information

Publications6

  1. ncbi Selective cannabinoid receptor 2 modulators: a patent review 2009 - present
    Doris Riether
    Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 65, D 88397 Biberach an der Riß, Germany
    Expert Opin Ther Pat 22:495-510. 2012
    ..While some of these have been terminated for various reasons, one can anticipate the emergence of new drugs from CB2 modulation once a better understanding around the cannabinoid receptors is gained...
  2. ncbi Nonsteroidal dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics
    Doris Riether
    Department of Medicinal Chemistry, Department of Immunology and Inflammation, and Drug Discovery Support, Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, Connecticut 06877, USA
    J Med Chem 53:6681-98. 2010
    ....
  3. ncbi 1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability
    Doris Riether
    Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 21:2011-6. 2011
    ..This class of compounds suffered from low metabolic stability. Following various strategies, compounds with a good stability in liver microsomes and rat PK profile have been identified...
  4. ncbi 5-Aminomethylbenzimidazoles as potent ITK antagonists
    Doris Riether
    Medicinal Chemistry Department, Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Rd PO Box 368, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 19:1588-91. 2009
    ..SAR studies around the benzylamines and the identification of 10n and 10o as excellent tools for proof-of-concept studies are described...
  5. ncbi Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters
    Renee Zindell
    Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877 0368, USA
    Bioorg Med Chem Lett 21:4276-80. 2011
    ..Structure-activity relationships are described with a focus on improving the drug-like parameters resulting in compounds with improved solubility and permeability...
  6. ncbi Morpholine containing CB2 selective agonists
    Renee Zindell
    Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877 0368, USA
    Bioorg Med Chem Lett 19:1604-9. 2009
    ..Identification and optimization of two classes of CB2 selective agonists are described. A representative from each class is profiled in a murine model of inflammation and each shows similar efficacy to prednisolone upon oral dosing...